Press Releases
Press Releases
More Press Releases
View Older Stories View Newer Stories-
Buzz Capital Inc. Announces Non-Brokered Private Placement
-
Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations
-
Fidelity Investments Canada Closes the Market
-
Autolus Therapeutics to Present Clinical Data Update at the American Society of Clinical Oncology Annual Meeting 2026
-
80% of Individual Contributors Say Their Manager’s Approach to AI is Hands-Off, FranklinCovey Research Finds
-
Defesio LLC CEO Believes That Health Care Organizations And Clinics Not Using Quantum Resistant Email May Not Be Technically HIPAA Compliant Anymore.
-
Logitech Files Annual Report on Form 10-K
-
Cleantek Industries Inc. First Quarter 2026 Interim Update
-
Equus Announces First Quarter Net Asset Value
-
Whale Dynamic Joins Hitch Open World AI Championships as Official Mapping Technology Partner, Delivering Centimeter-Accurate HD Map of Tianmen Mountain for 2026 Racing Season
-
Whitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for Use of CPT113 Linker-Payload
-
Remix Therapeutics Announces Positive Data from Phase 1/2 ARIA Study of First-in-Class MYB mRNA Degrader, REM-422, in Patients with Adenoid Cystic Carcinoma (ACC) at the American Society of Clinical O
-
Aulos Bioscience Reports Positive Phase 2 Data for Imneskibart in Doublet Checkpoint Inhibitor-Refractory Metastatic Melanoma at 2026 ASCO Annual Meeting
-
Natera to Present 35 Studies at ASCO, Extending Clinical Data Leadership in Oncology
-
Eikon Therapeutics Announces Availability of Six Abstracts for Presentation at the 2026 Annual Meeting of the American Society of Clinical Oncology
-
North American Construction Group Ltd. Announces Voting Results of Annual and Special Meeting of Shareholders
-
/C O R R E C T I O N -- VidantaWorld/
-
Fulgent Announces Rapid Oral Full Abstract Publication for FID-007 Within the Head and Neck Cancer Track Session at the ASCO 2026 Annual Meeting
-
Imperial Announces Voting Results for the Election of Directors
-
DATA Communications Management Corp. Report of Voting Results Annual and Special Meeting of Shareholders Held on May 21, 2026
-
Saturn Oil & Gas Inc. Announces Approval of All Resolutions and Voting Results of Annual and Special Shareholder Meeting
-
Moleculin Highlights Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting Highlighting Cardiac Safety Data for Annamycin
-
Lynozyfic® (linvoseltamab) Monotherapy Demonstrates Deep and Rapid Responses in All Treated Patients with Second-Line-Plus Systemic Amyloid Light Chain Amyloidosis
-
Agendia to Present New FLEX Study Data at ASCO 2026 Supporting NCCN Clinical Practice Guidelines in Oncology Update Recognizing MammaPrint for Guiding Anthracycline Use in Early-Stage Breast Cancer
-
Bristol Myers Squibb to Unveil New Data at ASCO® 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology Portfolio and Next-Generation Pipeline
-
Akari Therapeutics Reports Breakthrough Preclinical Data Demonstrating Synergistic Activity of AKTX-101 with KRAS Inhibition in KRAS-Mutated Pancreatic Cancer Models
-
Syndax Announces Four Revuforj® (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data
-
Medicure Announces AGM Results and Appointment of New Director
-
Medicure Reports Financial Results for Quarter Ended March 31, 2026 and Schedules May 25, 2026 Conference Call
-
IC Group Announces Q1 2026 Earnings Release Date and Investor Webinar
-
AerSale Announces Participation at the 2026 Jefferies Aftermarket MRO Virtual Summit
-
Boehringer Ingelheim’s oncology portfolio shows strong promise across multiple cancers at ASCO 2026
-
TruGolf Reports First Quarter 2026 Results
-
HiberCell to Present Preliminary Results from the Phase 1b Trial of GCN2 Activator HC-7366 when Combined with WELIREG® (belzutifan) for the Treatment of Late-Line Clear Cell Renal Cell Carcinoma (ccR
-
Canadian Net REIT Announces 2026 First-Quarter Results and a Distribution Increase
-
Asher Biotherapeutics Announces Two Presentations at the ASCO 2026 Annual Meeting Highlighting Clinical Progress Across Its CD8-Targeted Cytokine Pipeline
-
Zodiac Partners II, LLC Provides an Update to its Previously Announced $46 million Tender Offer to Acquire Destination XL Group, Inc. for $0.82 Per Share in Cash
-
NVIDIA Announces Upcoming Events for Financial Community
-
Accent Therapeutics to Present Trial in Progress Poster for Phase 1/2 Study of ATX-295 at the 2026 American Society of Clinical Oncology Annual Meeting
-
Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC
-
Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting
-
Lilly to showcase oncology portfolio across tumor types and treatment modalities at the 2026 American Society of Clinical Oncology Annual Meeting
-
Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy
-
WhiteFiber Signs AI Compute Agreement with Total Contract Value in Excess of $160 Million with Investment-Grade Technology Customer
-
Cardiff Oncology Announces Webcast to Discuss Updated Phase 2 CRDF-004 Data for Onvansertib in First-Line RAS-Mutated mCRC
-
Greenberg Traurig Bolsters Government Contracts and Space Practices with Shaun Kennedy in Denver
-
Lunit Highlights AI-Powered IHC and Tumor Microenvironment Research at ASCO 2026
-
New Clinical Data for Izalontamab Brengitecan and Novel ADC Pipeline to be Presented at ASCO 2026
-
Navient declares second quarter common stock dividend
-
Dell Technologies to Present at Investor Conference in June

